JP2021535149A5 - - Google Patents
Info
- Publication number
- JP2021535149A5 JP2021535149A5 JP2021510824A JP2021510824A JP2021535149A5 JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5 JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- seq
- her2 bispecific
- pharmaceutical product
- system inhibitor
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18191041 | 2018-08-27 | ||
| EP18191041.5 | 2018-08-27 | ||
| PCT/EP2019/072754 WO2020043683A1 (en) | 2018-08-27 | 2019-08-27 | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021535149A JP2021535149A (ja) | 2021-12-16 |
| JP2021535149A5 true JP2021535149A5 (https=) | 2022-08-12 |
| JPWO2020043683A5 JPWO2020043683A5 (https=) | 2022-08-12 |
| JP7459058B2 JP7459058B2 (ja) | 2024-04-01 |
Family
ID=63578931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510824A Active JP7459058B2 (ja) | 2018-08-27 | 2019-08-27 | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210246219A1 (https=) |
| EP (1) | EP3843849A1 (https=) |
| JP (1) | JP7459058B2 (https=) |
| KR (1) | KR20210052468A (https=) |
| CN (1) | CN112955221A (https=) |
| AU (1) | AU2019328632A1 (https=) |
| CA (1) | CA3106881A1 (https=) |
| WO (1) | WO2020043683A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020253034A1 (en) * | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CA3169910A1 (en) * | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
| US20230366884A1 (en) * | 2020-09-18 | 2023-11-16 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
| EP4281467A4 (en) * | 2021-01-25 | 2024-12-04 | Yuhan Corporation | Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody |
| CN117355319A (zh) | 2021-03-23 | 2024-01-05 | 皮里斯制药有限责任公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| EP4469476A1 (en) * | 2022-01-25 | 2024-12-04 | Merus N.V. | Combination therapy for the treatment of cancer |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN101355965A (zh) | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MX375378B (es) | 2013-09-27 | 2025-03-06 | Genentech Inc | Formulaciones de anticuerpos anti-pdl1. |
| WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2916923T3 (es) | 2014-07-11 | 2022-07-06 | Ventana Med Syst Inc | Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| KR20170138574A (ko) | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| JP6432121B2 (ja) | 2016-03-04 | 2018-12-05 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | Ｐｄｌ−１抗体、その医薬組成物及びその使用 |
-
2019
- 2019-08-27 CN CN201980071320.7A patent/CN112955221A/zh active Pending
- 2019-08-27 WO PCT/EP2019/072754 patent/WO2020043683A1/en not_active Ceased
- 2019-08-27 CA CA3106881A patent/CA3106881A1/en active Pending
- 2019-08-27 AU AU2019328632A patent/AU2019328632A1/en not_active Abandoned
- 2019-08-27 EP EP19756382.8A patent/EP3843849A1/en not_active Withdrawn
- 2019-08-27 JP JP2021510824A patent/JP7459058B2/ja active Active
- 2019-08-27 US US17/271,149 patent/US20210246219A1/en not_active Abandoned
- 2019-08-27 KR KR1020217007565A patent/KR20210052468A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535149A5 (https=) | ||
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Poletto et al. | Treatment strategies for patients with diffuse large B-cell lymphoma | |
| Choi et al. | T-cell agonists in cancer immunotherapy | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| Vacchelli et al. | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Cultrera et al. | Diffuse large B-cell lymphoma: current strategies and future directions | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| KR102786010B1 (ko) | 조합 및 이의 용도 | |
| JP2021525735A5 (https=) | ||
| JP2024505556A (ja) | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JP2024167261A (ja) | 抗原結合タンパク質 | |
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| JPWO2020043683A5 (https=) | ||
| WO2019177011A1 (ja) | 腫瘍免疫賦活剤 | |
| Lam et al. | Pharmacokinetics and pharmacodynamics of immunotherapy | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager | |
| Forero-Torres et al. | Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Preliminary results of a phase Ib/II dose-escalation study | |
| US20240166747A1 (en) | Antigen binding proteins and combinations thereof | |
| Deligne et al. | The vaccinal effect of monoclonal antibodies in cancer therapy | |
| Guo et al. | immunomodulatory drugs in |